mRNA vaccination, a model of transition from basic biology to medicine
CC BY.
Sixty years elapsed between the discovery of messenger RNA (mRNA) and the use of this molecule in an unprecedented global vaccination campaign that brought the Covid-19 pandemic under control. Sixty years of doubts for some and certainties for others about the possibility of using mRNA-an example of synthetic biology-in therapeutic medicine and vaccinology. Years of "translational" research and development have culminated in the success of anti-Covid-19 mRNA vaccines and the promise of more to come against emerging pathogens. A new paradigm in vaccinology, enabling pandemics to be tackled as they emerge. A lesson to be learned: medical progress is less a question of time than of the critical nature of the biological discovery that underpins it. Before leaving us, François Gros, who played a key role in the discovery of mRNA, was able to appreciate the relevance of this obvious fact.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:346 |
|---|---|
| Enthalten in: |
Comptes rendus biologies - 346(2024), S2 vom: 29. März, Seite 69-74 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Vaccination ARN messager (ARNm), modèle de transition de la biologie fondamentale à la médecine |
|---|
| Beteiligte Personen: |
Sansonetti, Philippe J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARNm |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 03.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5802/crbiol.129 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367219484 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367219484 | ||
| 003 | DE-627 | ||
| 005 | 20240403235242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.5802/crbiol.129 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM367219484 | ||
| 035 | |a (NLM)38231390 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Sansonetti, Philippe J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a mRNA vaccination, a model of transition from basic biology to medicine |
| 246 | 3 | 3 | |a Vaccination ARN messager (ARNm), modèle de transition de la biologie fondamentale à la médecine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CC BY | ||
| 520 | |a Sixty years elapsed between the discovery of messenger RNA (mRNA) and the use of this molecule in an unprecedented global vaccination campaign that brought the Covid-19 pandemic under control. Sixty years of doubts for some and certainties for others about the possibility of using mRNA-an example of synthetic biology-in therapeutic medicine and vaccinology. Years of "translational" research and development have culminated in the success of anti-Covid-19 mRNA vaccines and the promise of more to come against emerging pathogens. A new paradigm in vaccinology, enabling pandemics to be tackled as they emerge. A lesson to be learned: medical progress is less a question of time than of the critical nature of the biological discovery that underpins it. Before leaving us, François Gros, who played a key role in the discovery of mRNA, was able to appreciate the relevance of this obvious fact | ||
| 650 | 4 | |a Historical Article | |
| 650 | 4 | |a ARNm | |
| 650 | 4 | |a Biologie synthétique | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Vaccins | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Comptes rendus biologies |d 2002 |g 346(2024), S2 vom: 29. März, Seite 69-74 |w (DE-627)NLM117479551 |x 1768-3238 |7 nnns |
| 773 | 1 | 8 | |g volume:346 |g year:2024 |g number:S2 |g day:29 |g month:03 |g pages:69-74 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5802/crbiol.129 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 346 |j 2024 |e S2 |b 29 |c 03 |h 69-74 | ||